HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $19

HC Wainwright & Co. analyst Robert Burns has maintained a 'Buy' rating on Relay Therapeutics (NASDAQ: RLAY) and raised the price target from $14 to $19. This adjustment reflects a positive outlook on the company's performance.